Genome-wide association studies have implicated PLEXIN D1 (PLXND1) in body fat distribution and type 2 diabetes. However, a role for PLXND1 in regional adiposity and insulin resistance is unknown. Here we use in vivo imaging and genetic analysis in zebrafish to show that Plxnd1 regulates body fat distribution and insulin sensitivity. Plxnd1 deficiency in zebrafish induced hyperplastic morphology in visceral adipose tissue (VAT) and reduced lipid storage. In contrast, subcutaneous adipose tissue (SAT) growth and morphology were unaffected, resulting in altered body fat distribution and a reduced VAT:SAT ratio in zebrafish. A VAT-specific role for Plxnd1 appeared conserved in humans, as PLXND1 mRNA was positively associated with hypertrophic morphology in VAT, but not SAT. In zebrafish plxnd1 mutants, the effect on VAT morphology and body fat distribution was dependent on induction of the extracellular matrix protein collagen type V alpha 1 (col5a1). Furthermore, after high-fat feeding, zebrafish plxnd1 mutant VAT was resistant to expansion, and excess lipid was disproportionately deposited in SAT, leading to an even greater exacerbation of altered body fat distribution. Plxnd1-deficient zebrafish were protected from high-fat-diet-induced insulin resistance, and human VAT PLXND1 mRNA was positively associated with type 2 diabetes, suggesting a conserved role for PLXND1 in insulin sensitivity. Together, our findings identify Plxnd1 as a novel regulator of VAT growth, body fat distribution, and insulin sensitivity in both zebrafish and humans.
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zebrafish | body fat distribution | adipose development | insulin resistance | extracellular matrix T he regional distribution and morphology of adipose tissue (AT) are strong predictors of metabolic disease (1) (2) (3) . Excess lipid deposition in visceral AT (VAT; adipose associated with visceral organs) is associated with increased susceptibility to insulin resistance and type 2 diabetes (4), whereas expansion of subcutaneous AT (SAT; adipose between muscle and skin) is associated with reduced risk for metabolic disease and is even protective against hyperglycemia and dyslipidemia (4-7). In turn, hypertrophic AT morphology (few large adipocytes) is associated with insulin resistance and AT dysfunction, whereas hyperplastic AT morphology (many small adipocytes) is associated with improved metabolic parameters (4, (7) (8) (9) . Therefore, the identification of factors that regulate regional distribution and AT morphology could lead to new therapies to treat metabolic disease.
Genome-wide association studies have implicated the PLEXIN D1 (PLXND1) locus in waist:hip ratio (a measurement of regional AT distribution) and type 2 diabetes (10). However, a role for Plxnd1 in AT morphology, distribution, and metabolism is unknown. Plxnd1 is a transmembrane receptor that controls the migration, proliferation, and survival of diverse cell types (11) .
Mutation of Plxnd1 in mouse and zebrafish leads to hypervascularization in many tissues (12, 13) , and vascular endothelial cell Plxnd1 modulates extracellular matrix (ECM) synthesis and composition by regulating the collagen receptor, β1-integrin (14) . In turn, ECM provides a supportive microenvironment for AT growth and function (15) . For example, type V collagens regulate collagen fiber assembly, geometry, and strength (16, 17) , are up-regulated during adipogenesis, and can stimulate adipocyte differentiation in vitro (18) (19) (20) . However, the role of type V collagens during in vivo AT growth is unknown.
In this study, we use genetic analysis and in vivo imaging of lipid deposition dynamics in zebrafish to assess the role of Plxnd1 in AT morphology and body fat distribution. Previous studies have shown that zebrafish adipocytes and AT are morphologically, molecularly, and functionally homologous to mammalian white AT (21) (22) (23) (24) (25) (26) , and like mammals, zebrafish adipocytes accumulate a large cytoplasmic lipid droplet (LD) that facilitates the in vivo identification of adipocytes by fluorescent lipophilic dyes (21, 22, (24) (25) (26) . Here we determine in zebrafish that Plxnd1 functions through Col5a1 to exert a VAT-specific effect on adipose growth and morphology, resulting in altered body fat distribution and improved insulin sensitivity. In accord, molecular and physiological assessments in Significance PLEXIN D1 (PLXND1) has been implicated in body fat distribution and type 2 diabetes by genome-wide association studies, but the mechanism is unknown. We show here that Plxnd1 regulates body fat distribution in zebrafish by controlling the visceral adipose tissue (VAT) growth mechanism. Plxnd1 deficiency in zebrafish resulted in induction of a hyperplastic state and reduced lipid deposition in VAT. Regulation of VAT was dependent on the induction of the type V collagen, col5a1, suggesting that Plxnd1 controls body fat distribution by determining the status of VAT extracellular matrix. Plxnd1-deficient zebrafish were protected from high-fat-induced insulin resistance, and human PLXND1 mRNA was positively associated with type 2 diabetes. These results suggest that the role of Plxnd1 in body fat distribution and insulin signaling is conserved from zebrafish to humans.
humans support a conserved role for PLXND1 in regulation of VAT morphology and insulin sensitivity.
Results
Zebrafish plxnd1 Mutants Have Reduced Lipid Accumulation in VAT and Altered Body Fat Distribution. To test the role of Plxnd1 in body fat distribution, we first analyzed lipid deposition in homozygous Plxnd1 knockout mice; however, these mice die at birth before extensive formation of VAT (SI Appendix, Fig. S1 ). Therefore, we turned to the zebrafish model system. Homozygous plxnd1 null zebrafish mutants and their phenotypically normal siblings were stained with the neutral lipid dye Nile Red, and individual ATs were categorized into VAT, SAT or miscellaneous AT (cranial or associated with the skeleton) ( Fig. 1A and SI Appendix, Fig. S2A ). We then measured AT area, which has been previously shown to accurately predict triacylglyceride content (24) . Total AT area per fish was indistinguishable between plxnd1 mutants and siblings ( Fig. 1 A and B and SI Appendix, Fig. S2B ), and total extracted lipid levels per fish were identical (SI Appendix, Fig. S2C ). However, VAT area and volume were significantly decreased in plxnd1 mutants ( Fig. 1 A and B and SI Appendix, Fig. S2D ). In contrast, no significant change was observed between plxnd1 mutants and siblings in SAT or miscellaneous AT-localized lipid storage ( Fig.  1B and SI Appendix, Fig. S2D ), suggesting Plxnd1 exerts a VATspecific effect. The decrease in VAT area in plxnd1 mutants led to a reduced VAT:SAT ratio (Fig. 1B) . Thus, mutation of plxnd1 in zebrafish is associated with reduced lipid storage in VAT and altered body fat distribution.
Plxnd1 Deficiency Induces a Hyperproliferative and Hyperplastic State in Zebrafish VAT. We next quantified LD number and size as measures of hyperplastic and hypertrophic AT morphology (25) . Both sibling and plxnd1 mutant VAT had a bimodal distribution of LD sizes containing a population of very small LDs that was unaltered between genotypes ( Fig. 1 C and D) , as well as a second population of large LDs that was significantly smaller in plxnd1 mutants compared with in siblings ( Fig. 1 C and E) , of which the majority of EdU + nuclei belonged to either adipocytes or endothelial cells (Fig. 1F and SI Appendix, Fig. S4 ). Further, quantitative RT-PCR (qRT-PCR) revealed an increased expression of adipocyte differentiation genes (Fig. 1G ). In contrast, the morphology of plxnd1 SAT was indistinguishable from that of siblings (SI Appendix, Fig. S5 ). Together, these data demonstrate that Plxnd1 deficiency induces adipocyte hyperproliferation, induction of adipocyte differentiation genes, and hyperplastic VAT morphology without affecting SAT morphology.
PLXND1 mRNA Is Positively Associated with Hypertrophic Morphology in Human VAT, but not SAT. As Plxnd1 deficiency in zebrafish led to VAT-specific changes in morphology and altered body fat distribution, we next investigated whether a similar relationship existed in humans. Multiple regression analysis (adjusting for age and body mass index) revealed a positive association between VAT PLXND1 mRNA and more pronounced hypertrophic morphology in VAT (R 2 = 0.22 and P = 0.031) (Fig. 1H ), although no correlation was observed between PLXND1 mRNA and morphology in SAT (SI Appendix, Fig. S2E ). Thus, these data demonstrate that PLXND1 mRNA exhibits a VAT-specific association with morphology in humans, wherein greater levels of PLXND1 mRNA are associated with VAT hypertrophy and lower levels of PLXND1 mRNA are associated with hyperplastic VAT morphology. These data, together with the zebrafish data, suggest a conserved role for Plxnd1 in promoting hypertrophic VAT morphology.
Col5a1 Is Induced by Vascular Endothelial Cells of plxnd1 Mutant VAT.
Because Plxnd1 is known to modulate ECM synthesis and composition (14, 27) , we next analyzed ECM dynamics in plxnd1 mutant zebrafish. qRT-PCR revealed large-scale dysregulation of ECM components within plxnd1 mutant VAT ( Fig. 2A) . In general, ECM components were down-regulated (Fig. 2A) ; however, the type V collagens col5a1 and col5a3b were increased ( Fig. 2A) . Intriguingly, type V collagens have been previously shown to induce proliferation and differentiation of preadipocytes in vitro (19, 20) and regulate collagen fibrillogenesis to control ECM geometry and tensile strength (16, 17) , properties that have been implicated in metabolic dysfunction of obese AT (28) . Immunofluorescence confirmed an increase in Col5 protein and revealed specific localization to vascular endothelial cells in plxnd1 mutant VAT (Fig. 2 B-D and SI Appendix, Fig. S6 ), a site previously associated with COL5A1 protein localization in human AT (18) . FACS enrichment of endothelial cells followed by qRT-PCR determined that col5a1 mRNA was increased in plxnd1 mutant endothelial cells (Fig. 2E) , supporting a vascular endothelial cell origin for Col5a1 in plxnd1 mutant VAT.
Knockdown of Col5a1 Normalizes Hyperproliferation and Hyperplastic Morphology Within plxnd1 Mutant VAT. We hypothesized that induction of Col5a1 in plxnd1 mutant VAT establishes a microenvironment conducive to hyperplastic growth. To test this, we targeted zebrafish col5a1 with multiple, nonoverlapping vivo-morpholinos (vMOs). Serial injection of either vMO disrupted splicing of col5a1, and RT-PCR followed by sequencing confirmed the production of truncated col5a1 mRNAs predicted to be nonfunctional (col5a1-i1e2, 55 amino acids; col5a1-e3i3, 112 amino acids) (SI Appendix, Fig. S7 C and D) . Assessment of Col5 reactivity after injection of col5a1-i1e2 vMO revealed significantly reduced Col5 protein levels in both endothelial cell and periadipocyte locations (SI Appendix, Fig. S8 ). Injection of either col5a1 vMO did not affect proliferation or morphology of sibling VAT (Fig. 2 F-H) . However, in hyperplastic plxnd1 mutant VAT, injection of col5a1 vMO increased LD hypertrophy and induced the appearance of an additional population of very large LDs (μ3 = 122.59 μm; Fig. 2 F  and G) . Further, col5a1 vMO normalized levels of EdU + nuclei in plxnd1 mutant VAT (Fig. 2 F and H) , and volumetric analysis revealed a partial rescue of lipid storage in plxnd1 mutant VAT (Fig. 2I) , thus increasing the VAT:SAT ratio (Fig. 2J) . Therefore, Col5a1 is required for maintenance of the hyperplastic state of plxnd1 mutant VAT and the resulting body fat distribution.
plxnd1 Mutant VAT Undergoes Augmented Fibrillogenesis in a Col5a1-Dependent Manner. Our data suggest that zebrafish Plxnd1 modulates body fat distribution by determining the status of the VAT ECM microenvironment. To ascertain the architectural properties of ECM, we used the fluorescent collagen probe 5-(4,6-dichlorotriazinyl) aminofluorescein to label VAT-localized collagen fibers (SI Appendix, Fig. S9A ) (28) . ECM architecture of plxnd1 mutant VAT was markedly different from that of sibling VAT (Fig. 3A) and was characterized by larger and more numerous interstitial collagen fibers (Figs. 3A and SI Appendix, Fig.  S10 ). Moreover, plxnd1 mutant VAT had increased glycoprotein, elastin content (SI Appendix, Fig. S11) , and a greater abundance of fibrous ECM (SI Appendix, Fig. S11 ). plxnd1 mutant SAT did not have altered collagen or fibrous ECM (SI Appendix, Fig. S11 H and I), again demonstrating the starkly different response of VAT and SAT to Plxnd1 deficiency. To assess fibrillogenesis in plxnd1 mutant VAT, we extracted ECM from zebrafish VAT and induced polymerization and gel formation in vitro (SI Appendix, Fig. S12 ). We then conducted turbidity assays to determine the rate and ultimate extent of fibrillogenesis. Plxnd1-deficient VAT underwent an increased rate of fibrillogenesis compared with sibling ECM (Fig. 3B) , and plxnd1 mutant VAT attained a higher ultimate turbidity than sibling VAT (Fig. 3C) . Injection of col5a1-i1e2 vMO did not affect in vitro fibrillogenesis of sibling VAT; however, col5a1 vMO injection significantly reduced both the rate of fibrillogenesis and ultimate turbidity in plxnd1 mutant VAT (Fig. 3 B and C) . Therefore, ECM from plxnd1 mutant VAT has markedly different properties than wild-type VAT and undergoes augmented fibrillogenesis in a Col5a1-dependent manner. We next wished to test whether ECM of Plxnd1-deficient VAT is sufficient to instruct VAT cell proliferation and morphology. Isolated ECM from zebrafish VAT was used as a substrate for the culture of primary stromal vascular cells (SVCs) also isolated from zebrafish VAT (Fig. 3D) . When cultured within a 3D ECM substrate obtained from sibling VAT, sibling SVCs were able to proliferate and readily differentiate into adipocytes containing large LDs (Fig. 3 E and G) . In contrast, plxnd1 mutant SVCs cultured on ECM derived from plxnd1 mutant ECM reached a higher level of confluency (Fig. 3 E and F and SI Appendix, Fig.  S13A ), together with strikingly smaller LDs (Fig. 3 E and G and SI Appendix, Fig. S13A ). The degree of confluency and LD hypertrophy were ECM extract-dependent, as culturing sibling SVCs within ECM from plxnd1 mutants increased confluency and reduced LD size (Fig. 3 E-G) . Conversely, culturing plxnd1 mutant SVCs in sibling ECM abrogated the hyperproliferation and smaller LD size observed in the mutant experiment, leading to larger LDs more reminiscent of sibling:sibling cocultures (Fig.  3 E-G) . Moreover, combining ECM extract from siblings and plxnd1 mutants produced intermediate morphologies dependent on the proportion of wild-type sibling:plxnd1 mutant ECM (SI Appendix, Fig. S13 B and C) , suggesting that the capacity of plxnd1 mutant ECM to induce proliferation and hyperplastic morphology is proportional to the amount of plxnd1 mutant ECM present. Injection of col5a1 vMO before ECM extraction abrogated the ability of plxnd1 mutant ECM to induce proliferation and hyperplastic morphology in cultured plxnd1 mutant SVCs (SI Appendix, Fig. S13 D and E) . These data demonstrate that plxnd1 mutant ECM is sufficient to induce hyperproliferation of SVCs and a smaller overall size of LDs.
Lipid Is Preferentially Deposited in SAT of plxnd1 Mutants Fed a
High-Fat Diet. Considering the global obesity epidemic and the influence of body fat distribution on metabolic dysfunction, we next examined the effect of a high-fat diet on regional adiposity and metabolism in plxnd1 mutant zebrafish. We used daily immersion in 5% chicken egg yolk over the course of 2-3 wk as a highfat dietary supplement (HFD); this has previously been shown to induce lipid accumulation and metabolism in zebrafish (29) (30) (31) (32) . HFD treatment led to equivalent increases in lipid accumulation in both plxnd1/+ heterozygotes and homozygous plxnd1 mutants (Fig. 4 A and B and SI Appendix, Fig. S14A) . A substantial increase in total VAT and SAT area (SI Appendix, Fig. S14 B and C) and VAT and SAT LD size was observed in heterozygotes (Fig. 4 A, D-G) . However, VAT in HFD fed plxnd1 mutants did not expand (SI Appendix, Fig. S14B) , and VAT-LDs did not substantially increase in size (Fig. 4 A, D-G) . Strikingly, plxnd1 mutants underwent a larger expansion of SAT compared with heterozygotes (SI Appendix, Fig. S14C ), leading to supersized SAT-LDs (Fig. 4 A, E , and G) and a decreased VAT: SAT ratio (Fig. 4C) . Together, these data show that the absence of Plxnd1 results in a preferential expansion of SAT in response to HFD, and thus leads to further exacerbation of altered body fat distribution.
Plxnd1 Deficiency Protects Zebrafish from High-Fat Diet-Induced
Insulin Resistance. We hypothesized that decreased VAT:SAT ratio in plxnd1 mutants was associated with improved insulin sensitivity. HFD-fed wild-type siblings had hyperglycemia (Fig.  5A) . Further, after a glucose tolerance test, siblings fed a HFD failed to normalize blood glucose levels, suggesting a degree of systemic insulin resistance (Fig. 5B) . In contrast, plxnd1 mutants fed a HFD did not exhibit hyperglycemia (Fig. 5A) and efficiently normalized hyperglycemia after a glucose tolerance test (Fig. 5B) . The insulin receptor substrates 1 and 2 (irs1, irs2) are negatively regulated in insulin resistance (33) (34) (35) . However, in both control and HFD-fed plxnd1 VAT, irs1 and irs2 mRNAs were increased compared with siblings, supporting augmented insulin signaling in plxnd1 mutants (Fig. 5C ). Together, these data indicate that high-fat feeding induces a state reminiscent of insulin resistance in wild-type sibling zebrafish, and Plxnd1 deficiency protects from HFD-induced insulin resistance.
Increased PLXND1 mRNA in Human VAT Is Associated with Type 2 Diabetes. As Plxnd1 deficiency protects zebrafish from HFDinduced insulin resistance, we hypothesized PLXND1 mRNA would be positively associated with insulin resistance and type 2 diabetes in humans. Strikingly, analysis of PLXND1 mRNA levels in VAT and SAT from lean, healthy obese, and type 2 diabetic obese patients revealed that PLXND1 mRNA was specifically increased in VAT of obese patients with type 2 diabetes (Fig. 5D) , whereas no change was observed in SAT (Fig. 5D) or AT of healthy obese patients (Fig. 5D) , suggesting a role for VAT PLXND1 in insulin sensitivity. Moreover, in HFD-fed zebrafish that exhibit features of insulin resistance, VAT-localized plxnd1 mRNA was up-regulated (SI Appendix, Fig. S15D ), suggesting the positive association between VAT plxnd1 mRNA levels and insulin resistance is conserved to zebrafish. Discussion Genome-wide association studies have implicated PLXND1 in the regulation of body fat distribution and type 2 diabetes (10). However, a role for PLXND1 in regional adiposity has not been described, nor has direct evidence of a role in human metabolic disease been established. Our data establish three key points. First, Plxnd1 regulates body fat distribution by determining the growth characteristics of VAT. Second, the effect of Plxnd1 in VAT is mediated by Col5a1 and the establishment of an ECM microenvironment that is conducive to hyperplastic growth. Third, Plxnd1 deficiency protects zebrafish from HFD-induced insulin resistance and glucose intolerance, in accord with association data from humans showing that VAT PLXND1 mRNA levels correlate with insulin resistance and type 2 diabetes. Thus, our data suggest that Plxnd1 promotes VAT hypertrophy and growth and insulin resistance in both zebrafish and humans, and identifies PLXND1 as a new target for treatment of metabolic disease.
We propose a model whereby Plxnd1 regulates the mechanism of VAT growth by determining the status of the VAT ECM microenvironment (Fig. 5E and SI Appendix, Fig. S16 ). Our data show that in Plxnd1-deficient VAT, the induction of Col5a1 promotes adipocyte proliferation and differentiation, leading to hyperplastic VAT morphology and reduced lipid accumulation. Moreover, our data show that Col5a1 induction in plxnd1 mutants is localized to vascular endothelial cells, suggesting that blood vessels are the source of altered VAT morphology and body fat distribution. In normally fed animals, SAT is not significantly affected by Plxnd1 deficiency. However, after high-fat feeding of plxnd1 mutants, VAT fails to expand, and excess lipid is stored in SAT. Thus, we propose that impaired VAT expansion in plxnd1 mutants leads to increased, and perhaps compensatory, lipid storage in SAT. A VAT-specific role for Plxnd1 is supported by gene expression data from humans that show PLXND1 mRNA is positively correlated with hypertrophic morphology in VAT, with no association found between morphology and PLXND1 in SAT.
The relative abundance of VAT and SAT strongly influence susceptibility to metabolic disease. Previous studies suggest that impaired SAT expansion leads to increased lipid accumulation in VAT and subsequent metabolic complications (36) (37) (38) . As such, SAT acts as a "lipid buffer" that protects other tissues, including VAT, from excessive lipid exposure. In a similar manner, our HFD data suggest that impaired VAT growth in plxnd1 mutants positively influences lipid deposition in SAT. Intriguingly, the thiazolidinedione class of peroxisome-proliferator activated receptor ligands influences body fat distribution and decreases VAT:SAT ratio (39) (40) (41) . Interestingly, we observe an increase in pparg mRNA in both control and HFD-fed plxnd1 VAT, suggesting pparg induction within VAT may underlie the observed altered body fat distribution. In accordance, thiazolidinedione treatment has been shown to solely influence VAT growth in humans (40) , although other studies suggest SAT is also affected (39) . An increased proportion of small adipocytes in SAT is correlated with metabolic disturbance (38, 42) . We found plxnd1 mutants had an increased ratio of small:large LDs in VAT (SI Appendix , Fig. S17) ; however, as we observe increased proliferation and differentiation in plxnd1 mutant VAT, we believe this phenotype is likely different from the impaired differentiation observed in human insulinresistant SAT (38) .
Type V collagens have not been previously implicated in the regulation of in vivo AT growth or body fat distribution. Type V collagens are expressed by preadipocytes (43) and have a stimulatory effect on adipocyte hyperplasia (19) . Indeed, adipocyte differentiation is characterized by increased collagen V accumulation, followed by a decline in collagen V as adipose maturation proceeds (20) . Thus, collagen V is associated with "hyperplastic" adipose conditions. Our data support a role for Glucose tolerance tests reveal wild-type siblings fed a high-fat (HF) diet have a decreased capacity to normalize blood glucose relative to control-fed siblings (P < 0.001). plxnd1 mutants fed a control diet have an enhanced capacity to normalize blood glucose relative to control-fed siblings (P < 0.01), whereas plxnd1 mutants fed a HF diet have equivalent capacity to normalize experimentally induced hyperglycemia to control-fed siblings (P > 0.05). One-factor ANOVA followed by Tukey's HSD test (α = 0.05) was used to determine statistical significance at 120 min. Col5a1 in hyperplastic AT morphology. We speculate that Col5a1 may be selectively induced in situations in which hyperplastic growth is needed, such as insulin-resistant AT. Collagen in obese AT correlates with insulin resistance and metabolic disease and is thus often considered pathological (44) . Our data suggest that increased Col5a1 is metabolically beneficial. Intriguingly, AT of healthy children contains increased collagen accumulation that is correlated with decreased adipocyte size and body mass index (45) , suggesting AT collagen can be beneficial to AT growth and expansion in certain human contexts.
Methods
Human Experiments. All human studies were approved by the local committee on ethics at Karolinska Institutet. Informed consent was obtained from all participants. Detailed methods are included in SI Appendix.
Zebrafish and Mouse Experiments. All zebrafish and mouse experiments conformed to the Public Health Service Policy on Humane Care and Use of Laboratory Animals, using protocols approved by the Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill, Duke University, and the University of Pennsylvania. Detailed zebrafish methods are included in SI Appendix.
Statistics. Statistical analyses were conducted in GraphPad Prism 5.04 (GraphPad Software) or JMP Pro-11.0.0 (SAS Institute). For pairwise analyses, independent Student's t test was used to compare means assuming unequal variance: ns = not significant (P > 0.05); *P < 0.05; **P < 0.01; ***P < 0.001. One-way ANOVA followed by Tukey's HSD test was used when comparing three or more means. Groups with the same letters are not significantly different (α = 0.05). Probability density functions were used to describe the likelihood of LD sizes. Bars are mean ± SEM unless stated.
